Cargando…
Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
Targeted immunotherapy has arisen over the past decade to the forefront of cancer care. Notably, targeted therapies such as antibody-drug conjugates (ADCs) are becoming more recognized for a novel approach in cancer treatment. The mechanism of action of ADCs incorporates a monoclonal antibody portio...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Exploration
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400726/ https://www.ncbi.nlm.nih.gov/pubmed/36046359 http://dx.doi.org/10.37349/etat.2022.00067 |